Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease - Wikidata - awgldk - TriplyDB

Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease

Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease

http://www.wikidata.org/entity/Q35830757

about

Structure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the Drawbacks Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms Caffeine: cognitive and physical performance enhancer or psychoactive drug?Neurochemical measurement of adenosine in discrete brain regions of five strains of inbred mice The Safety of Ingested Caffeine: A Comprehensive Review.Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.Neurohormetic phytochemicals: An evolutionary-bioenergetic perspective Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism The emerging role of nutrition in Parkinson's disease.Exercise and Nutritional Benefits in PD: Rodent Models and Clinical Settings.Mediterranean diet and inflammaging within the hormesis paradigm.Health benefits of methylxanthines in neurodegenerative diseases.How does adenosine control neuronal dysfunction and neurodegeneration?The neuroprotective effects of caffeine in neurodegenerative diseases.Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches.Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use.Caffeine and Modafinil Ameliorate the Neuroinflammation and Anxious Behavior in Rats during Sleep Deprivation by Inhibiting the Microglia Activation.Beneficial Role of Coffee and Caffeine in Neurodegenerative Diseases: A Minireview.

P2860

Q26740559-801413E4-F0BF-478C-B44B-279B050DABB4 Q28075345-7558B661-1F5F-403A-99B0-93FE4C9A55B0 Q28080581-846B6FB8-4075-4B95-9A06-DC0993C39E2F Q28541087-CC843350-3E20-4082-BC3A-67879F8CE252 Q33729422-CB97318A-FC4B-42F9-ADCF-5EDC27E7ADE2 Q33971113-2B61B2CE-5385-4E40-87F9-2A588DE63A37 Q36101328-02134B9A-66BE-4BF5-A41F-041D92DFF033 Q36723079-091C5FF0-0C1B-4B88-862F-7517D19C2A9C Q37467929-6C03BBE3-4503-4C8D-8B80-E75CF8C30D8C Q37622710-C905044E-6094-4846-9752-7A6BF73C7B7E Q38686112-8D4557FF-2FFA-49BF-9A39-53D079B73A89 Q38736064-5B873CA7-7210-42A6-AE20-29FE8E6E0FD8 Q38772021-9724646A-9E03-4FFC-BD5A-7BEA48E29B05 Q38882782-EDA95131-6A67-4D26-ACDB-2E3A921B53A8 Q39186884-57261AAA-5D38-4E31-B4D3-7DADCD105E81 Q47137101-E2679917-A5D2-496C-9AE5-4596135F409F Q47851272-24602EB4-FA33-4B93-BB9C-05B21387D5B9 Q52620604-188F47A4-F1C7-48B8-B387-31C9BC325B07 Q54572410-37FE5A13-C788-436C-89A3-10B508B7BC1D

P2860

Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease

http://www.wikidata.org/entity/Q35830757

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Delayed caffeine treatment pre ...... t model of Parkinson's disease

@ast

Delayed caffeine treatment pre ...... t model of Parkinson's disease

@en

type

label

Delayed caffeine treatment pre ...... t model of Parkinson's disease

@ast

Delayed caffeine treatment pre ...... t model of Parkinson's disease

@en

prefLabel

Delayed caffeine treatment pre ...... t model of Parkinson's disease

@ast

Delayed caffeine treatment pre ...... t model of Parkinson's disease

@en

P1433

Q35830757-AD1C6F7C-0F2C-40C3-9C7E-B2DA7B11AA4B

P1476

Q35830757-7B985AB5-A016-42F5-8A31-EAD64AB3C1F8

P2093

Q35830757-060B80A6-3957-4C41-9256-8C19A93D0B70

Q35830757-180DC1BE-A90B-4175-9E92-A8AD8A718BBA

Q35830757-19CC620B-0A0B-40B1-B93C-9CE1F4D38A1D

Q35830757-2B649A03-2774-49D6-94AC-F5A328FCE024

Q35830757-3AF09633-918B-4923-93C3-7C656B9A02D8

Q35830757-3C39C43C-E657-4AB4-A06A-E4727445D770

Q35830757-FE2D6A7C-3D26-4AB0-8DB7-DD43109BAFB6

P2860

Q35830757-093F8BF9-97E9-4759-BD2A-1F0A970B544E

Q35830757-1190FAC3-7AAA-4603-94E3-2A611946B729

Q35830757-1F5314DC-12EF-4A30-83EF-483D7519DD09

Q35830757-20A59208-5618-4171-837D-CA7D3227F43F

Q35830757-21B39196-AA99-4382-9A57-B9662A329FBE

Q35830757-23D959DA-582F-4391-AB72-560B4F322FB9

Q35830757-2F5819D7-9DE4-44AA-82F0-442336BFD074

Q35830757-2FD5E215-E373-4412-BA12-FDB2CB005457

Q35830757-2FFE5A49-69CD-47AB-8890-0F7BF70B4755

Q35830757-3C401D24-0124-4929-B72F-987A2FC9F3CA

P304

Q35830757-BBAFFB68-DAF4-4471-8245-45842F1F154D

P31

Q35830757-9237D0E4-7A2C-444E-A2E8-E1242E988FC4

P356

Q35830757-C7D07945-2471-4FAC-90E8-B0079110A908

P407

Q35830757-E2228712-62E4-4E33-AF94-C821941C71EE

P433

Q35830757-AE666AA6-834A-4835-B3A5-D9BB5F9973B0

P478

Q35830757-FAD9D848-F741-45D2-BA44-54873D24B850

P50

Q35830757-BFEE815E-9895-44A0-B827-B7DBB266F516

P577

Q35830757-D82B73F4-2475-44A0-89AF-DCD4780C4C0F

P5875

Q35830757-00EA7F53-980E-47C2-A316-AB9664B24BDB

P698

Q35830757-5BF3FF5B-1E5A-4DF6-9F82-31F5CFCFB430

P921

Q35830757-06511242-8aea-4261-8993-5a56ac47f5fc

Q35830757-A7D88CF6-96CF-492B-A21D-187DEB6E4086

P932

Q35830757-0DD90A7A-FDEC-4885-A339-1E7E8A2400C1

P356

J.EXPNEUROL.2012.01.022

P1433

Experimental Neurology

P1476

Delayed caffeine treatment pre ...... t model of Parkinson's disease

@en

P2093

Bharathi S Gadad

http://www.w3.org/2001/XMLSchema#string

Dwight C German

http://www.w3.org/2001/XMLSchema#string

Ida Khobahy

http://www.w3.org/2001/XMLSchema#string

Lai-Yoong Wong

http://www.w3.org/2001/XMLSchema#string

Patricia K Sonsalla

http://www.w3.org/2001/XMLSchema#string

Suzan L Harris

http://www.w3.org/2001/XMLSchema#string

Wenhao Li

http://www.w3.org/2001/XMLSchema#string

P2860

Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.

Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

Adenosine A(2A) receptor mediates microglial process retraction

Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).

Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration

Higher serum caffeine in smokers with schizophrenia compared to smoking controls.

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

P304

482-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EXPNEUROL.2012.01.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

234

http://www.w3.org/2001/XMLSchema#string

P50

Jason R. Richardson

P577

2012-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221810253

http://www.w3.org/2001/XMLSchema#string

P698

22309831

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3303955

http://www.w3.org/2001/XMLSchema#string